These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 24387139)

  • 1. Long-term follow-up of peripheral lymphocyte subsets in a cohort of multiple sclerosis patients treated with natalizumab.
    Koudriavtseva T; Sbardella E; Trento E; Bordignon V; D'Agosto G; Cordiali-Fei P
    Clin Exp Immunol; 2014 Jun; 176(3):320-6. PubMed ID: 24387139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lymphocyte subsets show different response patterns to in vivo bound natalizumab--a flow cytometric study on patients with multiple sclerosis.
    Harrer A; Pilz G; Einhaeupl M; Oppermann K; Hitzl W; Wipfler P; Sellner J; Golaszewski S; Afazel S; Haschke-Becher E; Trinka E; Kraus J
    PLoS One; 2012; 7(2):e31784. PubMed ID: 22363732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients.
    Plavina T; Muralidharan KK; Kuesters G; Mikol D; Evans K; Subramanyam M; Nestorov I; Chen Y; Dong Q; Ho PR; Amarante D; Adams A; De Sèze J; Fox R; Gold R; Jeffery D; Kappos L; Montalban X; Weinstock-Guttman B; Hartung HP; Cree BAC
    Neurology; 2017 Oct; 89(15):1584-1593. PubMed ID: 28916537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiparametric flow cytometric analysis of whole blood reveals changes in minor lymphocyte subpopulations of multiple sclerosis patients.
    Teniente-Serra A; Grau-López L; Mansilla MJ; Fernández-Sanmartín M; Ester Condins A; Ramo-Tello C; Martínez-Cáceres E
    Autoimmunity; 2016 Jun; 49(4):219-28. PubMed ID: 26829210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of CD4+ CD8+ double-positive T cells in blood, cerebrospinal fluid and multiple sclerosis lesions.
    Waschbisch A; Sammet L; Schröder S; Lee DH; Barrantes-Freer A; Stadelmann C; Linker RA
    Clin Exp Immunol; 2014 Aug; 177(2):404-11. PubMed ID: 24730443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term decrease in VLA-4 expression and functional impairment of dendritic cells during natalizumab therapy in patients with multiple sclerosis.
    de Andrés C; Teijeiro R; Alonso B; Sánchez-Madrid F; Martínez ML; Guzmán de Villoria J; Fernández-Cruz E; Sánchez-Ramón S
    PLoS One; 2012; 7(4):e34103. PubMed ID: 22496780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High interindividual variability in the CD4/CD8 T cell ratio and natalizumab concentration levels in the cerebrospinal fluid of patients with multiple sclerosis.
    Harrer A; Pilz G; Wipfler P; Oppermann K; Sellner J; Hitzl W; Haschke-Becher E; Afazel S; Rispens T; van der Kleij D; Trinka E; Kraus J
    Clin Exp Immunol; 2015 Jun; 180(3):383-92. PubMed ID: 25603898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD4/CD8 ratio during natalizumab treatment in multiple sclerosis patients.
    Carotenuto A; Scalia G; Ausiello F; Moccia M; Russo CV; Saccà F; De Rosa A; Criscuolo C; Del Vecchio L; Brescia Morra V; Lanzillo R
    J Neuroimmunol; 2017 Aug; 309():47-50. PubMed ID: 28601287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Lab Data in Natalizumab Treated Multiple Sclerosis Patients Up to 6 Years Long-Term Follow Up.
    Kaufmann M; Haase R; Proschmann U; Ziemssen T; Akgün K
    Front Neurol; 2018; 9():1071. PubMed ID: 30581413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natalizumab therapy for highly active pediatric multiple sclerosis.
    Kornek B; Aboul-Enein F; Rostasy K; Milos RI; Steiner I; Penzien J; Hellwig K; Pitarokoili K; Storm van's Gravesande K; Karenfort M; Blaschek A; Meyer A; Seidl R; Debelic D; Vass K; Prayer D; Kristoferitsch W; Bayas A
    JAMA Neurol; 2013 Apr; 70(4):469-75. PubMed ID: 23420110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adhesion molecules are promising candidates to establish surrogate markers for natalizumab treatment.
    Wipfler P; Oppermann K; Pilz G; Afazel S; Haschke-Becher E; Harrer A; Huemer M; Kunz A; Golaszewski S; Staffen W; Ladurner G; Kraus J
    Mult Scler; 2011 Jan; 17(1):16-23. PubMed ID: 20937631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis.
    Stüve O; Marra CM; Bar-Or A; Niino M; Cravens PD; Cepok S; Frohman EM; Phillips JT; Arendt G; Jerome KR; Cook L; Grand'Maison F; Hemmer B; Monson NL; Racke MK
    Arch Neurol; 2006 Oct; 63(10):1383-7. PubMed ID: 17030653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased B cell and cytotoxic NK cell proportions and increased T cell responsiveness in blood of natalizumab-treated multiple sclerosis patients.
    Mellergård J; Edström M; Jenmalm MC; Dahle C; Vrethem M; Ernerudh J
    PLoS One; 2013; 8(12):e81685. PubMed ID: 24312575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The frequency of occurrence of atypical lymphocytes in peripheral blood smears of natalizumab-treated patients with multiple sclerosis.
    Robier C; Amouzadeh-Ghadikolai O; Bregant C; Diez J; Melinz K; Quehenberger F; Quasthoff S
    Int J Lab Hematol; 2017 Oct; 39(5):469-474. PubMed ID: 28481019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of natalizumab on circulating CD4+ T-cells in multiple sclerosis.
    Börnsen L; Christensen JR; Ratzer R; Oturai AB; Sørensen PS; Søndergaard HB; Sellebjerg F
    PLoS One; 2012; 7(11):e47578. PubMed ID: 23226199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune cells after prolonged Natalizumab therapy: implications for effectiveness and safety.
    Marousi S; Karkanis I; Kalamatas T; Travasarou M; Paterakis G; Karageorgiou CE
    Acta Neurol Scand; 2013 Jul; 128(1):e1-5. PubMed ID: 23311457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JC virus detection and JC virus-specific immunity in natalizumab-treated multiple sclerosis patients.
    Mancuso R; Saresella M; Hernis A; Marventano I; Ricci C; Agostini S; Rovaris M; Caputo D; Clerici M
    J Transl Med; 2012 Dec; 10():248. PubMed ID: 23232085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of lymphocytosis and CD4/CD8 ratio on the anti-JCV antibody index and clinical data in patients treated with natalizumab.
    Kolcava J; Hulova M; Rihova L; Bednarik J; Stourac P
    Neurol Sci; 2021 Jul; 42(7):2847-2853. PubMed ID: 33201361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunological markers of optimal response to natalizumab in multiple sclerosis.
    Villar LM; García-Sánchez MI; Costa-Frossard L; Espiño M; Roldán E; Páramo D; Lucas M; Izquierdo G; Álvarez-Cermeño JC
    Arch Neurol; 2012 Feb; 69(2):191-7. PubMed ID: 22332187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No evidence of JC virus reactivation in natalizumab treated multiple sclerosis patients: an 18 month follow-up study.
    Rinaldi L; Rinaldi F; Perini P; Calabrese M; Seppi D; Grossi P; Mattisi I; Barzon L; Mengoli C; Sanzari M; Palú G; Gallo P
    J Neurol Neurosurg Psychiatry; 2010 Dec; 81(12):1345-50. PubMed ID: 20547618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.